Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimers Disease: Design, synthesis, and characterization of pyrazines

Journal of Medicinal Chemistry

Volumn 55, Issue 21, 2012, Pages 9107-9119

  Berg, Stefan ^a   Bergh, Margareta ^a   Hellberg, Sven ^a   Högdin, Katharina ^a   Lo Alfredsson, Yvonne ^a   Söderman, Peter ^a   Von Berg, Stefan ^a   Weigelt, Tatjana ^a   Ormö, Mats ^b   Xue, Yafeng ^b   Tucker, Julie ^c   Neelissen, Jan ^a   Jerning, Eva ^a   Nilsson, Yvonne ^a   Bhat, Ratan ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; PYRAZINE DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CRYSTALLIZATION; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CATTLE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PERMEABILITY; PHOSPHORYLATION; PYRAZINES; SOLUBILITY; SULFONAMIDES; TAU PROTEINS;

EID: 84868534145     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201724m     Document Type: Article

References (21)

1. Alzheimer, A. Über eigenartige krankheitsfälle des späteren alters Z. Gesamte Neurol. Psychiatr. 1911, 4, 356-385
2. Yankner, B. A. Mechanisms of neuronal degeneration in Alzheimers disease Neuron 1996, 16, 921-932
3. Pei, J. J.; Braak, H.; Grundke-Iqbal, I.; Winblad, B.; Cowburn, R. F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimerss disease neurofibrillary changes J. Neuropathol. Exp. Neurol. 1999, 58 (9) 1010-1019
4. Leroy, K.; Boutajangout, A.; Authelet, M.; Woodget, J. R.; Anderton, B. H.; Brion, J.-P. The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimers disease Acta Neuropathol. 2002, 103, 91-99
5. Bhat, R. V.; Budd Haeberlein, S. L.; Avila, J. Glycogen synthase kinase 3: a drug target for CNS therapies J. Neurochem. 2004, 89, 1313-1317
6. Lucas, J. J.; Hernandez, F.; Gomez-Ramos, P.; Moran, M. A.; Hen, R.; Avila, J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration on GSK3beta conditional transgenic mice EMBO J. 2001, 20, 27-39
7. Kypta, R. M. Review: GSK3 inhibitors and their potential in the treatment of Alzheimers disease Expert Opin. Ther. Pat. 2005, 15 (10) 1315-1331
8. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. E.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a Series of Cyclin-Dependent Kinas Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity J. Med. Chem. 1999, 42, 2909-2919
9. Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25 Eur. J. Biochem. 2000, 267, 5983-5994
10. Coghlan, M. P.; Culbert, A. A.; Cross, D. A. E.; Corcoran, S. L.; Yates, J. W.; Pearce, N. J.; Rausch, O. L.; Murphy, G. J.; Carter, P. S.; Cox, L. R.; Mills, D.; Brown, M. J.; Haigh, D; Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A. D.; Holder, J. C. Selective small molecule inhibitors of glycogen synthse kinase-3 modulate glycogen metabolism and gene transcription Chem. Biol. 2000, 7 (9) 793-803
11. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormö, M.; Nilsson, Y.; Radesäter, A.-C.; Jerning, E.; Markgren, P.-O.; Borgegård, T.; Nylöf, M.; Giménez-Cassina, A.; Hérnández, F.; Lucas, J. J.; Díaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 J. Biol. Chem. 2003, 46 (278) 45937-45945
12. Uno, Y.; Iwashita, H.; Tsukamoto, T.; Uchiyama, N.; Kawamoto, T.; Kori, M.; Nakanishi, A. Efficacy of a novel, orally active GSK-3 inhibitor 6-methyl- N -[3-[[3(1-methylethoxy)propyl]carbamoyl]-1 H -pyrazol-4-yl]pyridine-3- carboxamide in tau transgenic mice Brain Res. 2009, 1296, 148-163
13. Ellingson, R. C.; Henry, R. L. Pyrazine Chemistry. IV. Bromination of 2-Amino-3-carbomethoxypyrazine J. Am. Chem. Soc. 1949, 71 (8) 2798-2800
14. Zhang, N.; Zhong, R.; Yan, H.; Jiang, Y. Structural Features Underlying Selective Inhibition of GSK3β by Dibromocantharelline: Implications for Rational Drug Design Chem. Biol. Drug. Des. 2011, 77, 199-205
15. Cecchelli, R.; Dehouck, B.; Descamps, L.; Fenart, L.; Buee-Scherrer, V.; Duhem, C.; Lundquist, S.; Rentfel, M.; Torpier, G.; Dehouck, M. P. In vitro model for evaluating drug transport across the bloo-brain barrier Adv. Drug Delivery Rev. 1999, 5, 165-178
16. Berg, S.; Hellberg Arylamines for the treatment of conditions associated with GSK-3. PCT Int. Appl. WO 2003004472 A1 20030116, 2003.
17. Gatti McArthur, S.; Goetschi, E.; Palmer, W. S., Preparation of acetylenyl-pyrazolo-pyrimidine derivatives for use as mglur2 antagonists treating CNS disorders, PCT Int. Appl. WO 2006099972 A1 20060928, 2006.
18. Richardson, C. M.; Nunns, C. L.; Williamson, D. S.; Parratt, M. J.; Dokurno, P.; Howes, R.; Borgognoni, J.; Drysdale, M. J.; Finch, H.; Hubbard, R. E.; Jackson, P. S.; Kierstan, P.; Lentzen, G.; Moore, J. D.; Murray, J. B.; Simmonite, H.; Surgenor, A. E.; Torrance, C. J. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping Bioorg. Med. Chem. Lett. 2007, 17 (14) 3880-3885
19. Venuti, M. C.; Stephenson, R. A.; Alvarez, R.; Bruno, J. J.; Strosberg, A. M. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogs of 1,2,3,5-tetrahydro-2- oxoimidazo[2,1- b ]quinazoline J. Med. Chem. 1988, 31, 2136-2145
20. Ellingson, R. C.; Henry, R. L. Pyrazine Chemistry. IV. Bromination of 2-Amino-3-carbomethoxypyrazine J. Am. Chem. Soc. 1949, 71 (8) 2798-2800
21. Stauffer, S. R.; Huang, Y. R.; Aron, Z. D.; Coletta, C. J.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists Bioorg. Med. Chem. 2001, 9, 151-162